ReviewNature biotechnology2004
Systems biology in drug discovery.
Review in Nature biotechnology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 167 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
167 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014.American journal of respiratory and critical care medicine · 2015Pooled it
- Retinal proteomics in neurodegeneration: Insights into ocular and brain disorders.Neural regeneration research · 2026Article
- Dynamic modelling of cell cycle arrest through integrated single-cell and mathematical modelling approaches.PLoS computational biology · 2025Article
- A bioprinted animal patient-derived breast cancer model for anti-cancer drug screening.Materials today. Bio · 2025Article
- Boron Nanocomposites for Boron Neutron Capture Therapy and in Biomedicine: Evolvement and Challenges.Biomaterials research · 2025Review
- Bridging academia and industry: advancing systems biology and QSP education through AstraZeneca's collaborative partnerships.Frontiers in systems biology · 2025Review
- Uses of Molecular Docking Simulations in Elucidating Synergistic, Additive, and/or Multi-Target (SAM) Effects of Herbal Medicines.Molecules (Basel, Switzerland) · 2024Review
- PKCActa pharmaceutica Sinica. B · 2024Article
- Revisiting drug-protein interaction prediction: a novel global-local perspective.Bioinformatics (Oxford, England) · 2024Article
- Identifying patterns to uncover the importance of biological pathways on known drug repurposing scenarios.BMC genomics · 2024Article
- OTTM: an automated classification tool for translational drug discovery from omics data.Briefings in bioinformatics · 2023Article
- A coarse-grained resource allocation model of carbon and nitrogen metabolism in unicellular microbes.Journal of the Royal Society, Interface · 2023Article
- Clinical Network Systems Biology: Traversing the Cancer Multiverse.Journal of clinical medicine · 2023Review
- Systems biology platform for efficient development and translation of multitargeted therapeutics.Frontiers in systems biology · 2023Article
- Targeted Therapy and Personalized Medicine.Cancer treatment and research · 2023Article
- Small molecule photocatalysis enables drug target identification via energy transfer.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Multi-parametric functional imaging of cell cultures and tissues with a CMOS microelectrode array.Lab on a chip · 2022Article
- Circadian and Immunity Cycle Talk in Cancer Destination: From Biological Aspects to In Silico Analysis.Cancers · 2022Review
- Utilizing graph machine learning within drug discovery and development.Briefings in bioinformatics · 2021Article
- A Novel Method for Colorectal Cancer Screening Based on Circulating Tumor Cells and Machine Learning.Entropy (Basel, Switzerland) · 2021Article
107 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The hope of the rapid translation of 'genes to drugs' has foundered on the reality that disease biology is complex, and that drug development must be driven by insights into biological responses. Systems biology aims to describe and to understand the operation of complex biological systems and ultimately to develop predictive models of human disease. Although meaningful molecular level models of human cell and tissue function are a distant goal, systems biology efforts are already influencing drug discovery. Large-scale gene, protein and metabolite measurements ('omics') dramatically accelerate hypothesis generation and testing in disease models. Computer simulations integrating knowledge of organ and system-level responses help prioritize targets and design clinical trials. Automation of complex primary human cell-based assay systems designed to capture emergent properties can now integrate a broad range of disease-relevant human biology into the drug discovery process, informing target and compound validation, lead optimization, and clinical indication selection. These systems biology approaches promise to improve decision making in pharmaceutical development.
Indexed as
Identifiers
15470465What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.